Doose Syndrome - Pipeline Insight, 2024

Doose Syndrome - Pipeline Insight, 2024

DelveInsight’s, ''Doose Syndrome - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Doose Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Doose Syndrome Understanding

Doose Syndrome (DRE) is defined as the persistence of seizures despite at least two syndrome-adapted antiseizure drugs (ASD) used at efficacious daily dose. Despite the increasing number of available ASD, about a third of patients with epilepsy still suffer from drug resistance. Several factors are associated with the risk of evolution to DRE in patients with newly diagnosed epilepsy, including epilepsy onset in the infancy, intellectual disability, symptomatic epilepsy and abnormal neurological exam.

Classification of the epilepsies into distinct electroclinical epilepsy syndromes has been one of the most significant achievements of modern epileptology. Syndromic diagnosis can provide clinicians with a framework to describe the clinical course, outline prognosis, and make correct therapeutic decisions.

Epilepsy syndromes may be identified early in the course of the seizure disorder, sometimes even at the time of initial diagnosis. However, in some cases, the clinical features may not fulfill those required for an established electroclinical epilepsy syndrome, and the epilepsy, therefore, remains undetermined or incompletely classified. In even fewer instances, a fully specified syndrome may be reclassified to another apparently unrelated syndrome in the course of the disease. In these cases, initial information at diagnosis may be difficult to interpret, or the epilepsy syndrome may be in evolution over time with additional information coming to light to allow more precise later identification.

""Doose Syndrome - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Doose Syndrome pipeline landscape is provided which includes the disease overview and Doose Syndrome treatment guidelines. The assessment part of the report embraces, in depth Doose Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Doose Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence R&D Doose Syndrome. The therapies under development are focused on novel approaches to treat/improve Doose Syndrome.

Doose Syndrome Emerging Drugs

Fintepla: Zogenix

Fintepla (fenfluramine) oral solution is a prescription medication approved by the FDA and EMA, and under regulatory review with PMDA (Japan), for the treatment of seizures associated with Dravet syndrome in patients two years of age and older.

Fintepla: Zogenix

Fintepla, formerly known as ZX-008, is a low dose of fenfluramine, a drug that blocks the reuptake of serotonin. Zogenix is developing it for Doose syndrome and other rare epilepsies in addition to Dravet and Lennox-Gastaut syndromes. These epilepsies tend to appear in childhood, have a higher mortality rate than other types of epilepsy and do not respond to many of the drugs typically used to treat seizures.

Further product details are provided in the report……..

Doose Syndrome: Therapeutic Assessment

This segment of the report provides insights about the Doose Syndrome drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Doose Syndrome

There are approx. 5+ key companies which are developing the therapies Doose Syndrome. The companies which have their Doose Syndrome drug candidates in the most advanced stage, i.e phase III include GW Pharmaceuticals

• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Doose Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Doose Syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Doose Syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Doose Syndrome drugs.

Doose Syndrome Report Insights

• Doose Syndrome Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Doose Syndrome Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Doose Syndrome drugs?
• How many Doose Syndrome drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Doose Syndrome?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Doose Syndrome therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Doose Syndrome and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Zogenix
• Jazz Pharmaceuticals
• GW Pharmaceuticals

Key Products

• Fintepla
• ZYN002
• Cannabidiol